Top

Published in:

01-06-2013 | Original Article

Recommendations for Preclinical Research in Hemorrhagic Transformation

Authors: Susan C. Fagan, Paul A. Lapchak, David S. Liebeskind, Tauheed Ishrat, Adviye Ergul

Published in: Translational Stroke Research | Issue 3/2013

Abstract

Hemorrhagic transformation (HT) is an important complication of ischemic stroke and is responsible for most of the mortality associated with acute reperfusion therapy. Although many important publications address the preclinical models of ischemic stroke, there are no current recommendations on the conduct of research aimed at understanding the mechanisms and consequences of HT. The purpose of this review is to present the various models used in HT research, the clinical correlates, and the experimental variables known to influence the quantitation of HT in preclinical investigation. Lastly, recommendations for the conduct of preclinical research in HT are provided.

Del Zoppo GJ, Zeumer H, Harker LA. Thrombolytic therapy in stroke: possibilities and hazards. Stroke. 1986;17(4):595–607.PubMedCrossRef

Fiorelli M, Bastianello S, von Kummer R, del Zoppo GJ, Larrue V, Lesaffre E, et al. Hemorrhagic transformation within 36 hours of a cerebral infarct: relationships with early clinical deterioration and 3-month outcome in the European Cooperative Acute Stroke Study I (ECASS I) cohort. Stroke. 1999;30(11):2280–4.PubMedCrossRef

Hacke W, Kaste M, Bluhmki E, Brozman M, Davalos A, Guidetti D, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008;359(13):1317–29.PubMedCrossRef

No Author. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med. 1995;333(24):1581–7.

Eissa A, Krass I, Bajorek BV. Optimizing the management of acute ischaemic stroke: a review of the utilization of intravenous recombinant tissue plasminogen activator (tPA). J Clin Pharm Ther. 2012. doi:10.1111/j.1365-2710.2012.01366.x.

Heo JH, Lucero J, Abumiya T, Koziol JA, Copeland BR, del Zoppo GJ. Matrix metalloproteinases increase very early during experimental focal cerebral ischemia. J Cereb Blood Flow Metab. 1999;19(6):624–33.PubMedCrossRef

del Zoppo GJ, Frankowski H, Gu YH, Osada T, Kanazawa M, Milner R, et al. Microglial cell activation is a source of metalloproteinase generation during hemorrhagic transformation. J Cereb Blood Flow Metab. 2012;32(5):919–32.PubMedCrossRef

Kamijyo Y, Garcia JH, Cooper J. Temporary regional cerebral ischemia in the cat. A model of hemorrhagic and subcortical infarction. J Neuropathol Exp Neurol. 1977;36(2):338–50.PubMedCrossRef

de Courten-Myers GM, Kleinholz M, Wagner KR, Myers RE. Fatal strokes in hyperglycemic cats. Stroke. 1989;20(12):1707–15.PubMedCrossRef

10.

Lapchak PA, Chapman DF, Zivin JA. Metalloproteinase inhibition reduces thrombolytic (tissue plasminogen activator)-induced hemorrhage after thromboembolic stroke. Stroke. 2000;31(12):3034–40.PubMedCrossRef

11.

Yenari MA, Lee LK, Beaulieu C, Sun GH, Kunis D, Chang D, et al. Thrombolysis with reteplase, an unglycosylated plasminogen activator variant, in experimental embolic stroke. J Stroke Cerebrovasc Dis. 1998;7(3):179–86.PubMedCrossRef

12.

Asahi M, Asahi K, Wang X, Lo EH. Reduction of tissue plasminogen activator-induced hemorrhage and brain injury by free radical spin trapping after embolic focal cerebral ischemia in rats. J Cereb Blood Flow Metab. 2000;20(3):452–7.PubMedCrossRef

13.

Chen CH, Manaenko A, Zhan Y, Liu WW, Ostrowki RP, Tang J, et al. Hydrogen gas reduced acute hyperglycemia-enhanced hemorrhagic transformation in a focal ischemia rat model. Neuroscience. 2010;169(1):402–14.PubMedCrossRef

14.

Sun L, Zhou W, Heiland S, Marti HH, Veltkamp R. A translationally relevant thromboembolic stroke model for the study of secondary hemorrhage after thrombolysis in rats. Brain Res. 2011;1368:346–54.PubMedCrossRef

15.

Qin Z, Karabiyikoglu M, Hua Y, Silbergleit R, He Y, Keep RF, et al. Hyperbaric oxygen-induced attenuation of hemorrhagic transformation after experimental focal transient cerebral ischemia. Stroke. 2007;38(4):1362–7.PubMedCrossRef

16.

Fagan SC, Kozak A, Hill WD, Pollock DM, Xu L, Johnson MH, et al. Hypertension after experimental cerebral ischemia: candesartan provides neurovascular protection. J Hypertens. 2006;24(3):535–9.PubMedCrossRef

17.

Murata Y, Rosell A, Scannevin RH, Rhodes KJ, Wang X, Lo EH. Extension of the thrombolytic time window with minocycline in experimental stroke. Stroke. 2008;39(12):3372–7.PubMedCrossRef

18.

Copin JC, Merlani P, Sugawara T, Chan PH, Gasche Y. Delayed matrix metalloproteinase inhibition reduces intracerebral hemorrhage after embolic stroke in rats. Exp Neurol. 2008;213(1):196–201.PubMedCrossRef

19.

Lu A, Clark JF, Broderick JP, Pyne-Geithman GJ, Wagner KR, Khatri P, et al. Mechanical reperfusion is associated with post-ischemic hemorrhage in rat brain. Exp Neurol. 2009;216(2):407–12.PubMedCrossRef

20.

Hu Q, Ma Q, Zhan Y, He Z, Tang J, Zhou C, et al. Isoflurane enhanced hemorrhagic transformation by impairing antioxidant enzymes in hyperglycemic rats with middle cerebral artery occlusion. Stroke. 2011;42(6):1750–6.PubMedCrossRef

21.

Fagan SC, Garcia JH. Hemorrhagic transformation in focal cerebral ischemia: influence of time to artery reopening and tissue plasminogen activator. Pharmacotherapy. 1999;19(2):139–42.PubMedCrossRef

22.

Fagan SC, Nagaraja TN, Fenstermacher JD, Zheng J, Johnson M, Knight RA. Hemorrhagic transformation is related to the duration of occlusion and treatment with tissue plasminogen activator in a nonembolic stroke model. Neurol Res. 2003;25(4):377–82.PubMedCrossRef

23.

Henning EC, Latour LL, Hallenbeck JM, Warach S. Reperfusion-associated hemorrhagic transformation in SHR rats: evidence of symptomatic parenchymal hematoma. Stroke. 2008;39(12):3405–10.PubMedCrossRef

24.

Crumrine RC, Marder VJ, Taylor GM, Lamanna JC, Tsipis CP, Scuderi P, et al. Intra-arterial administration of recombinant tissue-type plasminogen activator (rt-PA) causes more intracranial bleeding than does intravenous rt-PA in a transient rat middle cerebral artery occlusion model. Exp Transl Stroke Med. 2011;3(1):10.PubMedCrossRef

25.

Choudhri TF, Hoh BL, Solomon RA, Connolly Jr ES, Pinsky DJ. Use of a spectrophotometric hemoglobin assay to objectively quantify intracerebral hemorrhage in mice. Stroke. 1997;28(11):2296–302.PubMedCrossRef

26.

Jia L, Chopp M, Zhang L, Lu M, Zhang Z. Erythropoietin in combination of tissue plasminogen activator exacerbates brain hemorrhage when treatment is initiated 6 hours after stroke. Stroke. 2010;41(9):2071–6.PubMedCrossRef

27.

Ishiguro M, Kawasaki K, Suzuki Y, Ishizuka F, Mishiro K, Egashira Y, et al. A Rho kinase (ROCK) inhibitor, fasudil, prevents matrix metalloproteinase-9-related hemorrhagic transformation in mice treated with tissue plasminogen activator. Neuroscience. 2012;220:302–12.PubMedCrossRef

28.

Yenari MA, Xu L, Tang XN, Qiao Y, Giffard RG. Microglia potentiate damage to blood–brain barrier constituents: improvement by minocycline in vivo and in vitro. Stroke. 2006;37(4):1087–93.PubMedCrossRef

29.

McColl BW, Rose N, Robson FH, Rothwell NJ, Lawrence CB. Increased brain microvascular MMP-9 and incidence of haemorrhagic transformation in obese mice after experimental stroke. J Cereb Blood Flow Metab. 2010;30(2):267–72.PubMedCrossRef

30.

Ishiguro M, Mishiro K, Fujiwara Y, Chen H, Izuta H, Tsuruma K, et al. Phosphodiesterase-III inhibitor prevents hemorrhagic transformation induced by focal cerebral ischemia in mice treated with tPA. PLoS One. 2010;5(12):e15178.PubMedCrossRef

31.

Haddad M, Beray-Berthat V, Coqueran B, Palmier B, Szabo C, Plotkine M, et al. Reduction of hemorrhagic transformation by PJ34, a poly(ADP-ribose)polymerase inhibitor, after permanent focal cerebral ischemia in mice. Eur J Pharmacol. 2008;588(1):52–7.PubMedCrossRef

32.

Garcia-Yebenes I, Sobrado M, Zarruk JG, Castellanos M, de la Perez OS, Davalos A, et al. A mouse model of hemorrhagic transformation by delayed tissue plasminogen activator administration after in situ thromboembolic stroke. Stroke. 2011;42(1):196–203.PubMedCrossRef

33.

Howells DW, Porritt MJ, Rewell SS, O’Collins V, Sena ES, van der Worp HB, et al. Different strokes for different folks: the rich diversity of animal models of focal cerebral ischemia. J Cereb Blood Flow Metab. 2010;30(8):1412–31.PubMedCrossRef

34.

Bacigaluppi M, Comi G, Hermann DM. Animal models of ischemic stroke. Part two: modeling cerebral ischemia. Open Neurol J. 2010;4:34–8.PubMed

35.

Guan W, Kozak A, El-Remessy AB, Johnson MH, Pillai BA, Fagan SC. Acute treatment with candesartan reduces early injury after permanent middle cerebral artery occlusion. Transl Stroke Res. 2011;2(2):179–85.PubMedCrossRef

36.

Bowes MP, Zivin JA, Thomas GR, Thibodeaux H, Fagan SC. Acute hypertension, but not thrombolysis, increases the incidence and severity of hemorrhagic transformation following experimental stroke in rabbits. Exp Neurol. 1996;141(1):40–6.PubMedCrossRef

37.

Elewa HF, Kozak A, Johnson MH, Ergul A, Fagan SC. Blood pressure lowering after experimental cerebral ischemia provides neurovascular protection. J Hypertens. 2007;25(4):855–9.PubMedCrossRef

38.

Guan W, Kozak A, Fagan SC. Drug repurposing for vascular protection after acute ischemic stroke. Acta Neurochir Suppl. 2011;111:295–8.PubMedCrossRef

39.

Kozak W, Kozak A, Johnson MH, Elewa HF, Fagan SC. Vascular protection with candesartan after experimental acute stroke in hypertensive rats: a dose–response study. J Pharmacol Exp Ther. 2008;326(3):773–82.PubMedCrossRef

40.

Ergul A, Elgebaly MM, Middlemore ML, Li W, Elewa H, Switzer JA, et al. Increased hemorrhagic transformation and altered infarct size and localization after experimental stroke in a rat model type 2 diabetes. BMC Neurol. 2007;7:33.PubMedCrossRef

41.

Elgebaly MM, Ogbi S, Li W, Mezzetti EM, Prakash R, Johnson MH, et al. Neurovascular injury in acute hyperglycemia and diabetes: a comparative analysis in experimental stroke. Transl Stroke Res. 2011;2(3):391–8.PubMedCrossRef

42.

Elgebaly MM, Prakash R, Li W, Ogbi S, Johnson MH, Mezzetti EM, et al. Vascular protection in diabetic stroke: role of matrix metalloprotease-dependent vascular remodeling. J Cereb Blood Flow Metab. 2010;30(12):1928–38.PubMedCrossRef

43.

Lo EH. Experimental models, neurovascular mechanisms and translational issues in stroke research. Br J Pharmacol. 2008;153 Suppl 1:S396–405.PubMed

44.

Kozak A, Ergul A, El-Remessy AB, Johnson MH, Machado LS, Elewa HF, et al. Candesartan augments ischemia-induced proangiogenic state and results in sustained improvement after stroke. Stroke. 2009;40(5):1870–6.PubMedCrossRef

45.

de Courten-Myers GM, Kleinholz M, Holm P, DeVoe G, Schmitt G, Wagner KR, et al. Hemorrhagic infarct conversion in experimental stroke. Ann Emerg Med. 1992;21(2):120–6.PubMedCrossRef

46.

Tejima E, Katayama Y, Suzuki Y, Kano T, Lo EH. Hemorrhagic transformation after fibrinolysis with tissue plasminogen activator: evaluation of role of hypertension with rat thromboembolic stroke model. Stroke. 2001;32(6):1336–40.PubMedCrossRef

47.

Zhang F, Wang S, Luo Y, Ji X, Nemoto EM, Chen J. When hypothermia meets hypotension and hyperglycemia: the diverse effects of adenosine 5′-monophosphate on cerebral ischemia in rats. J Cereb Blood Flow Metab. 2009;29(5):1022–34.PubMedCrossRef

48.

Zhang L, Zhang ZG, Zhang RL, Lu M, Adams J, Elliott PJ, et al. Postischemic (6-hour) treatment with recombinant human tissue plasminogen activator and proteasome inhibitor PS-519 reduces infarction in a rat model of embolic focal cerebral ischemia. Stroke. 2001;32(12):2926–31.PubMedCrossRef

49.

Lapchak PA. A clinically relevant rabbit embolic stroke model for acute ischemic stroke therapy development: mechanisms and targets. In: Lapchak PA, Zhang JH, editors. Translational stroke research: from target selection to clinical trials. New York: Springer Series in Translational Stroke Research: Springer; 2012. p. 541–84.CrossRef

50.

Dijkhuizen RM, Asahi M, Wu O, Rosen BR, Lo EH. Rapid breakdown of microvascular barriers and subsequent hemorrhagic transformation after delayed recombinant tissue plasminogen activator treatment in a rat embolic stroke model. Stroke. 2002;33(8):2100–4.PubMedCrossRef

51.

Hornig CR, Dorndorf W, Agnoli AL. Hemorrhagic cerebral infarction—a prospective study. Stroke. 1986;17(2):179–85.PubMedCrossRef

52.

Renou P, Sibon I, Tourdias T, Rouanet F, Rosso C, Galanaud D, et al. Reliability of the ECASS radiological classification of postthrombolysis brain haemorrhage: a comparison of CT and three MRI sequences. Cerebrovasc Dis. 2010;29(6):597–604.PubMedCrossRef

53.

Lapchak PA. Translational stroke research using a rabbit embolic stroke model: a correlative analysis hypothesis for novel therapy development. Transl Stroke Res. 2010;1(2):96–107.PubMedCrossRef

54.

Turner RJ, Jickling GC, Sharp FR. Are underlying assumptions of current animal models of human stroke correct: from STAIRs to high hurdles? Transl Stroke Res. 2011;2(2):138–43.PubMedCrossRef

55.

Machado LS, Sazonova IY, Kozak A, Wiley DC, El-Remessy AB, Ergul A, et al. Minocycline and tissue-type plasminogen activator for stroke: assessment of interaction potential. Stroke. 2009;40(9):3028–33.PubMedCrossRef

56.

Park JH, Ko Y, Kim WJ, Jang MS, Yang MH, Han MK, et al. Is asymptomatic hemorrhagic transformation really innocuous? Neurology. 2012;78(6):421–6.PubMedCrossRef

57.

Copin JC, Gasche Y. Effect of the duration of middle cerebral artery occlusion on the risk of hemorrhagic transformation after tissue plasminogen activator injection in rats. Brain Res. 2008;1243:161–6.PubMedCrossRef

Title: Recommendations for Preclinical Research in Hemorrhagic Transformation
Authors: Susan C. Fagan
Paul A. Lapchak
David S. Liebeskind
Tauheed Ishrat
Adviye Ergul
Publication date: 01-06-2013
Publisher: Springer-Verlag
Published in: Translational Stroke Research / Issue 3/2013
Print ISSN: 1868-4483
Electronic ISSN: 1868-601X
DOI: https://doi.org/10.1007/s12975-012-0222-5

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Recommendations for Preclinical Research in Hemorrhagic Transformation

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2013

RIGOR Guidelines: Escalating STAIR and STEPS for Effective Translational Research

Drug-Like Property Profiling of Novel Neuroprotective Compounds to Treat Acute Ischemic Stroke: Guidelines to Develop Pleiotropic Molecules

SAHIT Investigators—on the Outcome of Some Subarachnoid Hemorrhage Clinical Trials

Polymorphisms in ACVRL1 and Endoglin Genes are Not Associated with Sporadic and HHT-Related Brain AVMs in Dutch Patients

In Vivo Animal Stroke Models

Distal Occlusion of the Middle Cerebral Artery in Mice: Are We Ready to Assess Long-Term Functional Outcome?